Platelet derived growth factor receptor antagonist - BeyondSpring Pharmaceutical

Drug Profile

Platelet derived growth factor receptor antagonist - BeyondSpring Pharmaceutical

Alternative Names: MTLH 001

Latest Information Update: 22 Jan 2016

Price : $50

At a glance

  • Originator Wuxi MTLH Biotechnology
  • Developer BeyondSpring Pharmaceuticals; Shanghai Pharmaceutical Group
  • Class Antineoplastics; Peptides
  • Mechanism of Action Platelet-derived growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Jan 2016 Preclinical trials in Cancer in USA (unspecified route) before January 2016
  • 07 Jan 2016 BeyondSpring Pharmaceutical plans to file an IND application for Cancer in USA in 2016
  • 25 Mar 2010 Wuxi MTLH Biotechnology out-licenses platelet derived growth factor receptor antagonist to Shanghai Pharmaceuticals Group in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top